Pulmonary hypertension and chronic obstructive pulmonary disease: A case for treatment

Proceedings of the American Thoracic Society

Volumn 2, Issue 1, 2005, Pages 12-19

  Higenbottam, Tim ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Endothelin 1; Exercise limitation; Pulmonary hypertension; Tobacco smoke

Indexed keywords

AMBRISENTAN; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BOSENTAN; BRONCHODILATING AGENT; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ENDOTHELIN A RECEPTOR AGONIST; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FLUTICASONE; FORMOTEROL; ILOPROST; INFLUENZA VACCINE; NITRIC OXIDE; OXITROPIUM BROMIDE; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; SALBUTAMOL; SILDENAFIL; SITAXSENTAN; STEROID; TIOTROPIUM BROMIDE; UNIPROST; VASODILATOR AGENT;

APOPTOSIS; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EMPHYSEMA; EXERCISE TOLERANCE; HUMAN; KINESIOTHERAPY; LUNG RESECTION; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PNEUMONIA; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ADAPTATION, PHYSIOLOGICAL; ADRENERGIC BETA-AGONISTS; APOPTOSIS; BRONCHODILATOR AGENTS; DYSPNEA; EXERCISE THERAPY; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; MUSCLE FATIGUE; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING CESSATION;

EID: 17644425321     PISSN: 15463222     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1513/pats.200411-053SF     Document Type: Conference Paper

References (67)

1. Peto R, Lopez AD. Future worldwide health effects of current smoking patterns: In: Koop CE, Pearson CE, Schwartz MR, editors. Critical issues in global health. San Francisco: Jossey-Bass; 2001. pp. 154-561.
2. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S, Sandstrom T, Larsson K. Obstructive lung disease in northern Sweden studies: not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97:154-161.
3. Fletcher CR, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. London: Oxford University Press; 1976.
4. Anthonisen NR, Connet SE, Murray RP. Smoking and lung function of the Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-679.
5. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004;125:626-632.
6. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, Brody JS. Effects of cigarette smoke on the human epithelial cell transcriptome. Proc Natl Acad Sci USA 2004;104:10143-10148.
7. Aoshiba K, Tamaoki J, Nagai A. Acute cigarette smoke exposure induces apoptosis of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2001;281(6):L1392-L1401.
8. Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, Laine J, Sakai T, Korsmeyer SJ, Casper RF, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet 2001;28:355-360.
9. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y, Murohara T. Smoking cessation rapidly increases circulating progenitor cells in the peripheral blood. Atheroscler Thromb Vasc Biol 2004;24:1442-1447.
10. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000;15:915-921.
11. Bello-Matute G, Martun TR. Science review: apoptosis in acute lung injury. Crit Care 2003;7:35508.
12. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
13. Corsico A, Milanese M, Baraldo S, Casoni GL, Papi A, Riccio AM, Cerveri I, Saetta M, Brusasco V. Small airway morphology and lung function in the transition form normality to chronic airway obstruction. J Appl Physiol 2003;95:441-447.
14. Tuder RM, Petrache L, Elias J, Voelkel N, Henson P. Apoptosis and emphysema: the missing link. Am J Respir Crit Care Med 2003;28:551-554.
15. Wright JL, Tai H, Dai J, Churg A. Cigarette smoke induces rapid changes in gene expression in pulmonary arteries. Lab Invest 2002;82:1391-1398.
16. Hale KA, Niewoehner DE, Cosio MG. Morphologic changes in the muscular pulmonary arteries relationship to cigarette smoking airway disease and emphysema. Am Rev Respir Dis 1980;122:273-278.
17. Calverley PM, Boonsawar W, Cseke Z, Zhong N, Petersen S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
18. Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-686.
19. Nagle F, Balke B, Baptista G, Alleyia J, Howley E. Compatibility of progressive treadmill, bicycle and step tests based on oxygen uptake responses. Med Sci Sports 1971;3:149-154.
20. Statement of the American Thoracic Society. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
21. Bowen JB, Votto JJ, Thrall RS, Haggerty MC, Stockdale-Woolley R, Bandyopadhyay T, ZuWallack RL. Functional status and survival following pulmonary rehabilitiation. Chest 2000;118:697-703.
22. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small difference in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-1282.
23. Onorati P, Antonucci R, Vall G, Berton E, De Marco F, Serra P, Palange P. Non-invasive evaluation of gas exchange during a shuttle walking test vs a 6 minute walk test to assess exercise tolerance in COPD patients. Eur J Appl Physiol 2003;89:331-336.
24. Alverti A, Stevenson N, Dellaca RL, Mauro AL, Pedatti A, Caverley PM. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004;59:210-216.
25. Leach RM, Davidson AC, Chinn S, Twort CH, Cameron I, Bateman N. Portable liquid oxygen and exercise in severe respiratory disability. Thorax 1992;47:781-789.
26. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, et al. Result at 1 yr of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-368.
27. National Emphysema Treatment Trial Research Group. A randomised trial comparing lung volume reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-2073.
28. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1897-1901.
29. Paggiaro PL, Dahle R, Bakran I, Firth L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-780.
30. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on the ventilatory limitations during exercise in advanced COPD. Am J Respir Crit Care Med 2001;163:892-898.
31. Mador J, Bozkanat E, Aggarwal A, Shaffer M, Kufel TJ. Endurance and strength training in patients with COPD. Chest 2004;123:2036-2045.
32. Dolmage TE, Waddell TK, Maltais F, Guyatt GH, Todd TR, Keshavjee S, van Rooy S, Krip B, LeBlanc P, Goldstein RS. Influence of lung volume reduction surgery on exercise in patients with COPD. Eur Respir J 2004;23:269-277.
33. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of effects of salbutamol and ipratropium bromide on exercise tolerance in patients with COPD. Chest 2003;123:1810-1816.
34. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840.
35. Martinez FJ, Osa M, Whyte RI, Stetz J, Gay SE, Celli BR. Lung volume reduction surgery improves dyspnoea dynamic inflation and respiratory muscle function. Am J Respir Crit Care Med 1997;155:1984-1990.
36. Saey D, Debigare R, LeBlanc P, Mador MJ, Cote CH, Jobin J, Maltais F. Contractile leg fatigue after cycle exercise. Am J Resp Crit Care Med 2003;168:425-430.
37. Laude EA, Duffy N, Lawson R, Jones PW, Calverley PMA. Heliox treatment during exercise in COPD: a randomized controlled trial [abstract]. Am J Respir Crit Care Med 2004;169:468.
38. Weitzenblum E, Sautegean A, Ehrhart M, Mammosser M, Roegel E. Longterm course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984;130:993-998.
39. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. Natural history of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219-224.
40. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998;113:576-583.
41. Pepke-Zaba J, Higenbottam TW, Dinh Xuan AT. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;38:1173-1174.
42. Roger N, Barbera JA, Roca J, Rovira I, Gomez FP, Rodriguez-Roisin R. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:800-806.
43. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, Germann P, Block LH. A controlled prospective randomised trial on the effects pulmonary haemodynamics of ambulatory long term inhaled nitric oxide and oxygen un patients with severe COPD. Thorax 2003;58:289-293.
44. Agostoni P, Doria E, Galli C, Tomborini G, Gauzzi MD. Nefedipine reduces pulmonary pressure and vascular tone drug short but not long-term treatment of pulmonary hypertension in patients with COPD. Am Rev Respir Dis 1989;139:120-125.
45. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
46. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
47. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue in patients with pulmonary arterial hypertension: a double blind randomised controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
48. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277.
49. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
50. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist in patients with pulmonary arterial hypertension. Chest 2002;121:1860-1868.
51. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62S-67S.
52. Yamakami T, Taguchi O, Gabazza EC, Yoshida M, Kobayashi T, Kobayashi H, Yasui H, Ibata H, Adachi Y. Arterial endothelin-1 levels in pulmonary emphysema and interstitial lung disease: relationship with pulmonary hypertension with exercise. Eur Respir J 1997;10:2055-2060.
53. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:389-405.
54. Pearl JM, Wellmann SA, McNamara JL, Lombardi JP, Wagner CJ, Raake JL, Nelson DP. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg 1999;68:1714-1721.
55. Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M, Miyata K. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol 2004;496:129-139.
56. Scharf SM, Igbol M, Kellen C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patient with severe emphysema. Am J Respir Crit Care Med 2002;166:314-322.
57. Poulain M, Durand F, Palomba B, Ceugniet F, Desplan J, Varray A, Prefaut C. 6-Minute walk testing in more sensitive than maximum incremental cycle testing for the detecting oxygen desaturation in patients with COPD. Chest 2003;123:1401-1407.
58. Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, Barbera JA. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002;19:632-638.
59. Koyama S, Sato E, Haniuda M, Numanami H, Nagai S, Izumi T. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:382-385.
60. 2-dependent mechanism. FASEB J 2002;16:1463-1464.
61. Sekhon HS, Wright JL, Churg A. Cigarette smoke causes rapid cell proliferation in small airways and associated small arteries. Am J Physiol 1994;267:L557-L563.
62. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001;164:1038-1042.
63. Barbera JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001;164:709-713.
64. Haniuda M, Kubo K, Fujimoto K, Honda T, Yamaguchi S, Yashida K, Amano J. Effecte of pulmonary artery remodeling on pulmonary circulation after lung volume reduction surgery. Thorac Cardiovasc Surg 2003;51:154-158.
65. Moore LG, Shriver M, Bemis L, Hickler B, Wilson M, Brutsaert T, Parra E, Vargas E. Maternal adaptation to high altitude pregnancy: an experiment of nature. Placenta 2004;25(Suppl A):560-571.
66. Kuc RE, Davenport AP. Endothelin-A-receptors in human aorta and pulmonary arteries are down regulated in patients with cardiovascular disease: an adaptive response to increased levels of endothelin-1? J Cardiovasc Pharmacol 2000;36(5 Suppl 1):S377-S379.
67. Chen J, He L, Dinger B, Stensaas L, Fidone S. Role of endothelin and endothelin A-type receptor in adaptation of the carotid body to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2002;282:L1314-L1323.